Our research demonstrated that miR-320d could inhibit proliferation, migration, invasion, and EMT by inhibiting TUSC3, suggesting that miR-320d may be applied as a key therapeutic target for clinical treatment, providing a new strategy for the prevention and treatment of EGFR-positive CRC. This evidence concerns the gene TUSC3 and colorectal carcinoma.